Answers are grounded in this paper and cite their sources.
Background: Evolving data suggest that anticoagulation is safe in cirrhosis and may improve decompensation-free survival in select patients. This study aimed to assess the efficacy and safety of the direct oral anticoagulant apixaban in patients with cirrhosis. Methods: In this open-label randomized controlled trial with blinded endpoint assessment, adult patients (18–60y) with cirrhosis (Child-Pugh B7–C10) without splenoportal axis thrombosis were randomized (1:1) to receive apixaban (2.5 mg twice daily) along with standard medical therapy (SMT) or SMT alone for 12 months. The primary outcome was the comparison of the proportion of patients with hepatic decompensation at 1 year. Secondary outcomes included frequency of liver-related events, overall and liver-related mortality, and adverse events (AEs). Results: One hundred thirty-four patients (mean age 43.4±9.5 y; Child-Pugh B/C:115/19) were randomized (67 Apixaban+SMT and 67 SMT). Patients receiving apixaban experienced significantly lower rates of hepatic decompensation compared with SMT (33.1% vs. 54.3%; absolute risk reduction 21.2% [95% CI: 4.5%–38.2%]; p =0.013). Although rates of ascites (6.4% vs. 17.4%), HE (21.2% vs. 36.0%), and variceal bleeding (7.5% vs. 14.6%) were lower among patients receiving Apixaban+SMT as compared with SMT alone, the differences were not statistically significant. No significant between-group differences in all-cause and liver-related mortality at 1 year were noted. There were no significant between-group differences in AEs (55.2% vs. 53.7%), any bleeding (41.8% vs. 46.3%), and major bleeding (9.0% vs. 11.9%) events. Conclusions: Apixaban significantly reduced hepatic decompensation events without increasing hemorrhagic episodes in Child-Pugh B7-C10 cirrhosis (CTRI/2023/09/058018).
No takes yet. Share an insight, caveat, or question.
Agarwal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: